poisar

Stocks · News reference

BofA Securities Maintains Buy Rating on Amylyx Pharmaceuticals, Adjusts Price Target

Fiscal.ai

BofA Securities has reaffirmed its 'Buy' rating on Amylyx Pharmaceuticals while lowering the firm's price target to $37.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading